Ozempic, Wegovy maker Novo Nordisk questioned over high cost of weight-loss drugs
Senators on the U.S. Senate Health, Education, Labor and Pensions Committee questioned Novo Nordisk CEO Lars Fruergaard Jørgensen on Tuesday about the high costs of the company’s GLP-1 drugs. The company makes two of the popular drugs used for weight loss: …